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Abstract
Previously we reported that the variable heavy chain region (VH)
of a human beta2  glycoprotein I-dependent monoclonal
antiphospholipid antibody (IS4) was dominant in conferring the
ability to bind cardiolipin (CL). In contrast, the identity of the
paired variable light chain region (VL) determined the strength of
CL binding. In the present study, we examine the importance of
specific arginine residues in IS4VH and paired VL in CL binding.
The distribution of arginine residues in complementarity
determining regions (CDRs) of VH  and VL  sequences was
altered by site-directed mutagenesis or by CDR exchange. Ten
different 2a2 germline gene-derived VL  sequences were
expressed with IS4VH and the VH of an anti-dsDNA antibody, B3.
Six variants of IS4VH, containing different patterns of arginine
residues in CDR3, were paired with B3VL and IS4VL. The ability
of the 32 expressed heavy chain/light chain combinations to
bind CL was determined by ELISA. Of four arginine residues in
IS4VH CDR3 substituted to serines, two residues at positions
100 and 100 g had a major influence on the strength of CL
binding while the two residues at positions 96 and 97 had no
effect. In CDR exchange studies, VL containing B3VL CDR1
were associated with elevated CL binding, which was reduced
significantly by substitution of a CDR1 arginine residue at
position 27a with serine. In contrast, arginine residues in VL
CDR2 or VL CDR3 did not enhance CL binding, and in one case
may have contributed to inhibition of this binding. Subsets of
arginine residues at specific locations in the CDRs of heavy
chains and light chains of pathogenic antiphospholipid
antibodies are important in determining their ability to bind CL.
Keywords: antiphospholipid antibodies, arginine, binding, cardiolipin
Introduction
The identification of antiphospholipid antibodies (aPL) is a
key laboratory feature in the diagnosis of patients with
antiphospholipid antibody syndrome (APS). The cardinal
manifestations of this syndrome are vascular thrombosis,
recurrent pregnancy loss, livedo reticularis and thrombocy-
topenia [1,2]. APS may affect any organ of the body, lead-
ing to a broad spectrum of manifestations [3]. It is the
commonest cause of acquired hypercoagulability in the
general population [4] and a major cause of pregnancy
morbidity.
APS may occur as a 'freestanding' syndrome (primary APS)
[5] or in association with other autoimmune rheumatic dis-
eases (secondary APS) [6]. In both primary APS and sec-
ondary APS, recurrence rates of up to 29% for thrombosis
and a mortality of up to 10% over a 10-year follow-up
period have been reported [7]. The only treatment that
reduces the risk of thrombosis in APS is long-term antico-
agulation [8]. This treatment may have severe side effects,
notably bleeding. It is therefore important to develop a
greater understanding of how aPL interact with their target
antigens so that new treatments for APS, which are both
more effective and more accurately targeted to the causes
of the disease process, may be developed.
aPL = antiphospholipid antibodies; APS = antiphospholipid syndrome; β2GPI = beta2 glycoprotein I; CDR = complementarity determining region; CL 
= cardiolipin; dsDNA = double-stranded DNA; ELISA = enzyme-linked immunosorbent assay; Fab = antigen-binding fragment; VH = variable heavy 
chainregion; VL = variable light chainregion.Arthritis Research & Therapy    Vol 7 No 1    Giles et al.
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aPL occur in 1.5–5% of healthy people and may also occur
in various medical conditions without causing clinical fea-
tures of APS [9]. The aPL that are found in patients with
APS differ from those found in healthy people in that they
target predominantly negatively charged phospholipid anti-
bodies and are in fact directed against a variety of phos-
pholipid binding serum proteins. These proteins include
protein C, protein S, prothrombin and beta2 glycoprotein I
(β2GPI) [10-13]. β2GPI is the most extensively studied of
these proteins and appears to be the most relevant clini-
cally [14-16]. Furthermore, high levels of IgG aPL, rather
than IgM aPL, are closely related to the occurrence of
thrombosis in APS [17,18].
Sequence analysis of human monoclonal aPL has shown
that IgG aPL, but not IgM aPL, often contain large numbers
of somatic mutations in their variable heavy chain region
(VH) and variable light chain region (VL) sequences [19].
The distribution of these somatic mutations suggests that
they have accumulated under an antigen-driven influence
[20]. These monoclonal aPL tend to have accumulations of
arginine residues, asparagine residues and lysine residues
in their complementarity determining region (CDRs).
Arginine residues have also been noted to play an impor-
tant role in the CDRs of some murine monoclonal aPL
[21,22].
Arginine residues, lysine residues and asparagine residues
also occur very commonly in the CDRs of human and
murine antibodies to dsDNA (anti-dsDNA) [23-25], partic-
ularly arginine residues in VH CDR3 [25-27]. It has been
suggested that the structure of these amino acids allows
them to form charge interactions and hydrogen bonds with
the negatively charged DNA phosphodiester backbone
[25,28]. We hypothesise that the same types of interaction
may occur between negatively charged epitopes upon
phospholipid antibodies/β2GPI and arginine residues,
asparagine residues and lysine residues at the binding
sites of high-affinity pathogenic IgG aPL.
We have previously described a system for the in vitro
expression of whole IgG molecules from cloned VH and VL
sequences of human monoclonal aPL antibodies [29]. This
system was used to test the binding properties of combina-
tions of heavy chains and light chains derived from a range
of human antibodies. One of these antibodies, IS4, is an
IgG antibody derived from a primary APS patient. IS4 binds
to anionic phospholipid antibodies only in the presence of
β2GPI, can bind to β2GPI alone and is pathogenic in a
murine model [30]. It is therefore likely to be relevant in the
pathogenesis of APS.
We found that the sequence of IS4VH was dominant in con-
ferring the ability to bind cardiolipin (CL) while the identity
of the VL paired with this heavy chain was important in
determining the strength of CL binding [29].
Modelling studies have shown that multiple surface-
exposed arginine residues were prominent features of the
heavy chains and light chains that conferred the highest
ability to bind CL. The CDR3 region of IS4VH contains five
arginine residues, of which four are predicted by the model
to be surface-exposed, and therefore is potentially impor-
tant in binding to CL [29].
The purpose of the study reported in this paper was to
define the contribution of different CDRs, and of individual
arginine residues within those CDRs, in binding to CL. Pat-
terns of CDR arginine residues in the cloned VH and VL
sequences were altered by site-directed mutagenesis or by
CDR exchange. The altered heavy chains and light chains
were expressed transiently in COS-7 cells. Binding of the
different heavy chain/light chain combinations to CL was
tested by direct ELISA.
Materials and methods
Human monoclonal antibodies
IS4, B3 and UK4 are all human IgG monoclonal antibodies
produced from lymphocytes of three different patients. IS4
was derived from a primary APS patient by the Epstein–
Barr virus transformation of peripheral blood mononuclear
cells and fusion with the human-mouse heterohybridoma
K6H6/B5 cell line [31]. IS4 binds to CL in the presence of
bovine and human β2GPI, and to human β2GPI alone [31].
B3 [32] and UK4 [33] were isolated by fusion of peripheral
B lymphocytes from systemic lupus erythematosus patients
with cells of the mouse human heteromyeloma line CB-F7.
B3 binds single-stranded DNA, dsDNA, CL and histones
[32,34]. UK4 binds negatively charged (but not neutral)
phospholipid antibodies in the absence of β2GPI and does
not bind DNA [33].
Assembly of constructs for expression
Wild-type heavy chain and light chain constructs
Constructs containing the wild-type heavy chain and light
chain were prepared as detailed fully in previous articles
[29,35]. UK4VH could not be cloned into the appropriate
plasmid, hence only UK4VL was available for analysis. The
expression vectors (pLN10, pLN100 and pG1D210) were
all kind gifts from Dr Katy Kettleborough and Dr Tarran
Jones (Aeres Biomedical, London, UK).
Hybrid VL chain constructs
Each hybrid VL chain construct contained the CDR1 of one
of the human monoclonal IgG antibodies IS4, B3 or UK4
and the CDR2 and CDR3 of a different one of these anti-
bodies. Two hybrid VL chains (BU and UB) had previously
been made by Dr Haley and colleagues [36], and a furtherAvailable online http://arthritis-research.com/content/7/1/R47
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four chains (IB, IU, BI and UI) were made by a similar
method, as follows.
Two different wild-type VL  expression vectors were
digested with Acc65 I and Pvu I (Promega, Southampton,
UK). Acc65 I cuts IS4, B3 or UK4 VL sequences at a posi-
tion in FR2 that is 106 base pairs from the beginning of VL,
but does not cut the expression vector outside the insert.
Pvu I cuts the vectors at a single site approximately 1 kb
downstream of the insert. Each vector was therefore
digested into two linear bands; one of approximately 1.5 kb
and the other of approximately 6 kb. The 1.5 kb fragment
contained CDR2 and CDR3 of the IgG VL region and also
part of the downstream expression vector containing the
lambda constant region cDNA, while the 6 kb fragment
contained CDR1 and the rest of the vector. The 6 kb frag-
ment derived from one VL expression vector was ligated
with the 1.5 kb fragment derived from the other. The result-
ing plasmid would contain CDR1 of one VL sequence and
CDR2 and CRD3 of another VL sequence.
Since IS4, B3 and UK4 VL sequences differ in their content
of the restriction sites Aat II and Ava I, we checked that the
desired parts of each sequence were present in the new
hybrid sequences by carrying out Aat II, Hind III/Ava I and
Aat II/Bam HI digests.
Site-directed mutagenesis of IS4VH
We generated six mutant forms of IS4VH in which particular
arginine residues were mutated to serine, using the Quik-
Change site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) according to the manufacturer's protocol. Serine
was chosen because it is nonpolar. Germline reversion
could not be performed because the exact germline DH
gene of IS4VH CDR3 is unknown. Four mutants, named
IS4VHi, IS4VHii, IS4VHiii and IS4VHiv, contained single
mutations of arginine residues at positions 96, 97, 100 and
100 g, respectively. The remaining two forms contained
two arginine to serine mutations, at positions 96 and 97 in
the IS4VHi&ii mutant and at all four sites in mutant IS4VHx.
Expression of whole IgG molecules
The whole IgG molecules were expressed in COS-7 cells
as described previously [29,37].
Detection and quantitation of whole IgG molecules in 
COS-7 supernatant by ELISA
Whole IgG molecules were detected and quantitated in the
COS-7 cell supernatants using a direct ELISA, as
described in previous papers [29,35,37].
Detection of binding to CL by ELISA
The binding of IgG molecules to CL was measured by
direct ELISA as described previously [29].
Results
Sequences of light chains expressed
Amino acid sequences of IS4VL, UK4VL, B3VL and germ-
line gene 2a2 are shown in Fig. 1a. All of these light chains
contain numerous somatic mutations. Previous statistical
analysis has shown that the observed pattern of replace-
ment mutations in the CDRs of these sequences is consist-
ent with antigen-driven selection [32,33,35,38-40]. The
light chain B3aVL, shown in Fig. 1a, was derived from B3VL
by site-directed mutagenesis of Arg27a to serine [37].
The VL sequences of IS4, B3 and UK4 are all encoded by
the germline Vλ gene 2a2, but differ in their patterns of
somatic mutation. B3Vλ contains two adjacent arginine res-
idues in CDR1, both produced by somatic mutations.
UK4Vλ has a single somatic mutation to arginine in CDR3
at position 94. A serine residue in CDR3 of IS4VL  is
replaced by asparagine.
Figure 1a also shows the amino acid sequences of the Vλ
CDR hybrids in which each newly formed chain construct
contains CDR1 of one antibody with CDR2 and CDR3 of
a different antibody. These hybrid sequences were named
by combining the names of the two parent antibodies such
that the first letter represented the antibody from which
CDR1 was derived and the last letter represented the anti-
body from which both CDR2 and CDR3 were derived.
Hybrid IB thus contains CDR1 from IS4, and CDR2 and
CDR3 from B3, whereas hybrid BI contains the reverse
combination (CDR1 from B3, and CDR2 and CDR3 from
IS4).
Sequences of heavy chains expressed
The amino acid sequences of IS4VH and B3VH chain and
the corresponding germline genes are displayed in Fig. 1b.
B3VH has a single somatic mutation to arginine in CDR2.
The CDR2 of IS4VH contains an asparagine residue cre-
ated by somatic mutation and in CDR3 there are multiple
arginine residues, which are highly likely to have arisen as a
result of antigen-driven influence. The four surface-exposed
arginine residues that were mutated to serine to create the
six mutant forms of IS4VH are underlined in Fig. 1b.
Expression of whole IgG
Each of the 10 light chains shown in Fig. 1a was paired
with B3VH and IS4VH. Each of the six mutant forms of
IS4VH was paired with IS4VL and B3VL. A total of 32 heavy
chain/light chain combinations were expressed in COS-7
cells. At least two expression experiments were carried out
for each combination. IgG was obtained in the supernatant
for all of the combinations.
The range of concentrations of IgG obtained in COS-7 cell
supernatants, determined by ELISA, from each of the 32
heavy chain/light chain combinations are presented inArthritis Research & Therapy    Vol 7 No 1    Giles et al.
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Table 1. Identical concentrations were obtained for the
combination IS4VHii/B3VL from two different expression
experiments. In each case the negative control sample, in
which COS-7 cells were electroporated without any plas-
mid DNA, contained no detectable IgG. Consistently high
yields were obtained with the B3VH/BIVL, B3VH/UIVL and
IS4VH/UIVL combinations compared with the other anti-
body combinations. The phenomenon of variable expres-
sion with different VH and VL constructs is well documented
both in this antibody expression system and in other sys-
tems [35,37], although the reason for the occurrence of
variable expression is not clear.
Results of anti-CL ELISA
For each heavy chain/light chain combination that bound
CL, the linear portion of the binding curve for absorbance
against antibody concentration was determined empiri-
cally, by dilution of antibody over a wide range of concen-
trations. Similar patterns of binding were obtained for each
combination from repeated expression experiments, hence
representative results from a single experiment only are
shown in Figs 2,3,4.
The importance of arginine residues in IS4VH
As reported previously, the presence of the heavy chain of
IS4 plays a dominant role in binding to CL [29]. IS4VH
binds CL in combination with six of the 10 light chains
tested (see Figs 2a and 3): B3VL, B3aVL, BIVL, IS4VL, IBVL
and UIVL. Only one of these light chains (B3VL) binds CL in
combination with B3VH (Fig. 2b).
To identify the features of IS4VH that enhance binding to
CL, we focused on the combination IS4VH/B3VL. This com-
bination shows high binding to CL. This binding could be
altered by the replacement of some or all of the four sur-
face-exposed arginine residues in IS4VH CDR3 to serine,
as shown in Fig. 4. Substitution of all four arginine residues
with serine residues (IS4VHx) abolished CL binding com-
pletely. This effect seems probably due entirely to the
changes at positions 100 and 100 g. This is supported by
the fact that heavy chain combinations containing arginine
to serine mutations at these positions (IS4VHiii and
IS4VHiv) displayed approximately 50% weaker binding to
CL in combination with B3VL than did the wild-type IS4VH/
B3VL combination. In contrast, there were no reductions in
CL binding for the heavy chains containing arginine to ser-
ine mutations at position 96 (IS4VHi), at position 97
(IS4VHii) or at both positions (IS4VHi&ii).
The importance of arginine residues in the light chain CDRs
Six light chains bound CL in conjunction with IS4VH (Figs
2a and 3). The strongest binding was seen with light chains
containing B3VL CDR1, namely B3VL, B3aVL and BI VL, in
combination with IS4VH. In contrast, light chains IB and UB,
containing CDR2 and CDR3 from B3, showed weak bind-
ing and no binding to CL, respectively, in combination with
IS4VH.
To test the hypothesis that the arginine at position 27a in
B3VL CDR1 is responsible for the favourable effect of this
CDR on binding to CL, we expressed combinations of
IS4VH and B3VH with B3aVL, in which Arg27a has been
Figure 1
Sequence alignment of the expressed variable light chainregion (VL) and variable heavy chainregion (VH), using DNAplot software in VBASE [54] Sequence alignment of the expressed variable light chainregion (VL) and variable heavy chainregion (VH), using DNAplot software in VBASE. (a) 
Sequences of expressed Vλ regions compared with gene 2a2. (b) Sequences of expressed VH regions compared with genes 1-03 (IS4) and 3–23 
(B3). The DH regions could not be matched to germline genes. Arginine residues altered by site-directed mutagenesis to serine residues in IS4VH 
complementarity determining region (CDR) 3 are underlined. Amino acids are numbered according to Kabat. Dots inserted to facilitate the align-
ment. Dashes indicate homology with the corresponding germline sequence. FR, framework region.
(a) Lambda chains
FR1 CDR1 FR2 CDR2 FR3 CDR3 Jλ
1 2 0 2 4 2 7 3 4 3 5 4 0 5 0 6 07 08 08 9 1 0 0
abc
2a2 QSALTQPASVSG.SPGQSITISC TGTSSDVGGYNYVS WYQQHPGKAPKLMIY EVSNRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC SSYTSSST VVFGGGTKLTVLG
IS4 ------------.---------- --A---I-S—-S-- ---HL-------I-- D--S--- ------------F----------P-------- C---TIN- W------------
UK4 ------------.---------- ---SN---S----- ---L---E----L-- DAIK--- ---------E-----------------G---- ----NR.. –F-----------
B3 ------------.---------- ---RR------F-- --------------- ---H--- ---T---A----S------------------- ---S-TTR -------------
B3a ------------.---------- ---R-------F-- --------------- ---H--- ---T---A----S------------------- ---S-TTR -------------
IB ------------.---------- --A---I-S—-S-- --------------- ---H--- ---T---A----S------------------- ---S-TTR -------------
IU ------------.---------- --A---I-S—-S-- ---L---E----L-- DAIK--- ---------E-----------------G---- ----NR.. –F-----------
UI ------------.---------- ---SN---S----- ---HL-------I-- D--S--- ------------F----------P-------- C---TIN- W------------
UB ------------.---------- ---SN---S----- --------------- ---H--- ---T---A----S------------------- ---S-TTR -------------
BI ------------.---------- ---RR------F-- ---HL-------I-- D--S--- ------------F----------P-------- C---TIN- W------------
BU ------------.---------- ---RR------F-- ---L---E----L-- DAIK--- ---------E-----------------G---- ----NR.. –F-----------
(b) Heavy chains
FR1 CDR1 FR2 CDR2 FR3 CDR3 JH
30 31 36 40 50 60 70 82 90 100 101
abc
1-03 QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYAMH WVRQAPGQRLEWMG WINSGNGNTKYSQKFQG RVTITRDTSASTAYMELSSLRSEDTAVYYCAR YFDYWGQGTLVTVSS
IS4 ---F--------------------F--S-- --FL- --------GP---- -------------N--- --S--------VV-------G----------- GRRDVRGVLWRGRHD ---F-------I---
3-23 EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVS AISGSGGSTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK YFDYWGQGTLVTVSS
B3 ----V------------------T-----T T---- -------------- T---R-S-----G--Q- ---L------S--------------------- PNVGSGW S--S-----L-T---Available online http://arthritis-research.com/content/7/1/R47
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mutated to serine. As shown in Fig. 3, there was a signifi-
cant decrease in CL binding of B3VH/B3aVL compared
with B3VH/B3VL. Although the combination IS4VH/B3aVL
binds CL less strongly than does IS4VH/B3VL, reduction in
binding is not as great as that seen when these light chains
are combined with B3VH. This observation is consistent
with the idea that IS4VH plays a dominant role in binding to
CL.
Despite being tested at a range of concentrations up to 75
times higher than those that gave maximal CL binding for
the other combinations containing IS4VH, none of the light
chains containing CDR2 and CDR3 derived from UK4VL,
including UK4 wild-type, IU and BU, showed any binding to
CL.
Discussion
Previously we have shown the important roles played in
antigen binding by IS4VH and B3VL, which both contain
multiple nongermline-encoded arginine residues in their
CDRs, supporting the idea that this amino acid is important
in creating a CL binding site [29]. The results described in
the present study demonstrate that it is not just the pres-
ence of, but the precise location of arginine residues in the
CDRs that is important in determining the ability to bind CL.
Figure 2
Effect of complementarity determining region exchange in the light chains Effect of complementarity determining region exchange in the light chains. Cardiolipin binding of IgG in COS-7 cell supernatants containing wild-
type heavy chains expressed with wild-type or hybrid light chain constructs. (a) Light chains expressed with IS4 variable heavy chainregion (VH). (b) 
Light chains expressed with B3VH. Presented as concentration of IgG in the supernatant versus optical density (OD) at 405 nm in the anti-cardioli-
pin ELISA.
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The importance of arginine residues at specific positions in
the VH and VL sequences of anti-DNA antibodies has been
examined by many groups, by expressing the antibodies in
vitro  and then altering the sequence of the expressed
immunoglobulins by chain swapping or mutagenesis
[27,37,41-43]. In general, these studies have shown that
altering the numbers of arginine residues in the CDRs of
these antibodies can lead to significant alterations in bind-
ing to DNA. Arginines in VH CDR3 often play a particularly
important role in binding to this antigen [27,37,41-43].
Table 1
The range of IgG concentrations (ng/ml) produced by expression of the 32 heavy chain/light chain combinations
Heavy chain Light chain contributing CDR1 Light chain contributing CDR2 and CDR3 Light chain name IgG concentration (ng/ml)
IS4 IS4 IS4 IS4 24–368
IS4 IS4 B3 IB 22–140
IS4 IS4 UK4 IU 70–194
IS4 B3 B3 B3 5–14
IS4 B3 IS4 BI 50–60
IS4 B3 UK4 BU 5–60
IS4 UK4 UK4 UK4 11–22
IS4 UK4 IS4 UI 50–480
IS4 UK4 B3 UB 9–50
B3 IS4 IS4 IS4 71–192
B3 IS4 B3 IB 41–96
B3 IS4 UK4 IU 89–376
B3 B3 B3 B3 3.5–6
B3 B3 IS4 BI 120–608
B3 B3 UK4 BU 40–68
B3 UK4 UK4 UK4 8–28
B3 UK4 IS4 UI 60–480
B3 UK4 B3 UB 2–20
IS4 B3(Arg27aSer) B3 B3a 48–60
B3 B3(Arg27aSer) B3 B3a 2.5–4
IS4VHi IS4 IS4 IS4 50–56
IS4VHii IS4 IS4 IS4 65–70
IS4VHiii IS4 IS4 IS4 48–90
IS4VHiv IS4 IS4 IS4 48–90
IS4VHx IS4 IS4 IS4 78–94
IS4VHi&ii IS4 IS4 IS4 74–80
IS4VHi B3 B3 B3 24–54
IS4VHii B3 B3 B3 30
IS4VHiii B3 B3 B3 30–34
IS4VHiv B3 B3 B3 28–30
IS4VHx B3 B3 B3 32–34
IS4VHi&ii B3 B3 B3 32–47
IgG concentrations in COS-7 cell supernatants were determined by ELISA. The hybrid light chains were named by combining the names of the 
two parent antibodies such that the first letter represented the antibody from which the complementarity determining region (CDR) 1 was derived 
and the last letter represented the antibody from which both the CDR2 and CDR3 were derived. At least two expression experiments were carried 
out for each combination; identical concentrations were obtained for IS4VHii/B3VL from two different expression experiments.Available online http://arthritis-research.com/content/7/1/R47
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Behrendt and colleagues recently demonstrated that the
affinity of human phage-derived anti-dsDNA Fabs from a
lupus patient correlated with the presence of somatically
mutated arginine residues in CDR1 and CDR2 of the heavy
chain [44].
Previous studies of the contribution of aPL heavy chains or
light chains to CL binding have yielded conflicting results.
Different groups have reported important contributions
from the heavy chain [21,45], from the light chain [46], or
from both chains [43,47]. In one of these studies the role of
arginine residues was examined in a murine antibody (3H9)
with dual specificity for phospholipid antibodies and DNA
[21]. The introduction of arginine residues into the VH at
positions known to mediate DNA binding enhanced bind-
ing to phosphatidylserine–β2GPI complexes and to apop-
totic cell debris, which may be an important physiological
source of both these antigens [48].
Our data show that combinations of IS4VH with light chains
containing CDR1 of B3 (B3VL, B3aVL and BIVL) produced
the strongest binding to CL. The CDR1 of B3VL and BIVL
contains two surface-exposed arginine residues at posi-
tions 27 and 27a, while B3aVL contains only one arginine
at position 27. Previous modelling studies have suggested
that the binding of B3VH/B3VL to dsDNA is stabilised by
the interaction of dsDNA with Arg27a in CDR1 and Arg54
in CDR2 of the light chain [34]. Expression and mutagene-
sis studies from our group confirmed that mutation of
Arg27a to serine led to a reduction in binding to DNA [37].
In the present study the same change has been shown to
reduce binding to CL, supporting the conclusion of Cocca
and colleagues that arginines at particular positions can
enhance binding to both DNA and CL [21].
It is important, however, not to overlook the possible contri-
bution of other amino acids in B3VL to CL binding. For
example, substitution of histidine at position 53 with lysine
and substitution of serine at position 29 with glycine could
significantly influence the stability of the antigen binding
site. In fact, we have previously shown that introduction of
the Ser29 to glycine mutation in addition to the Arg27a to
serine mutation in the light chain of B3VL/B3VH leads to a
further reduction in binding to dsDNA [37].
The presence of UK4VL CDR2 and CDR3 in any light chain
blocked binding to CL, even when combined with B3VL
CDR1 (light chain BU). UK4VLCDR1, however, does not
block binding. We have previously shown that the pres-
ence of UK4VL CDR2 and CDR3 blocks binding to DNA
and histones but not to the Ro antigen [36,37]. Modelling
studies have shown that an arginine at position 94 in CDR3
of UK4VL hinders DNA binding sterically. A similar effect
may be occurring with regards to the binding of UK4VL to
CL.
The effect of point mutations of specific arginine residues
in CDR3 of IS4VH upon CL binding is shown in Fig. 4. The
low binding of IS4VH/IS4VL was abolished by inclusion of
any one of these mutations. This is not the case, however,
when these mutants are expressed with B3VL. In this case
the arginine residues at 100 and 100 g confer a greater
effect on CL binding compared with the arginine residues
at positions 96 and 97. Substitutions of all four of these
IS4VH CDR3 arginine residues were sufficient to com-
pletely abolish all binding to CL.
An accumulation of arginine residues in VH CDR3 has been
noted in most, but not in all, sequences of pathogenic mon-
oclonal aPL. From our detailed analysis of all published
sequences of monoclonal aPL we found that of 13 mono-
clonal aPL that had been examined in various biological
assays, eight monoclonal aPL had been shown to be path-
ogenic [49]. Three aPL derived from patients with primary
APS and a healthy subject induced a significantly higher
rate of foetal resorptions and a significant reduction in foe-
tal and placental weight following intravenous injection into
mated BALB/c mice [50,51]. Five other aPL derived from
patients with primary APS and systemic lupus erythemato-
sus/APS were found to be thrombogenic in an in vivo
model of thrombosis [30]. We compared the sequences of
these eight pathogenic antibodies with those of the other
five antibodies, observing no evidence of pathogenicity in
these bioassays. There was no evidence of preferential
gene usage in either antibody group and somatic mutations
were common in both groups. The presence of arginine
residues in VH CDR3, however, did differ between patho-
Figure 3
Effect of point mutation Arg27a to serine in B3 variable light chainre- gion (VL) complementarity determining region 1 Effect of point mutation Arg27a to serine in B3 variable light chainre-
gion (VL) complementarity determining region 1. Comparison of cardiol-
ipin binding of IgG in COS-7 cell supernatants containing wild-type 
heavy chains expressed with B3VL or B3VLa. Presented as concentra-
tion of IgG in the supernatant versus optical density (OD) at 405 nm in 
the anti-cardiolipin ELISA.
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genic aPL and nonpathogenic aPL. Six of the eight patho-
genic aPL, but only one of five nonpathogenic aPL, contain
at least two arginine residues in VH CDR3 [49].
Our data confirm that the effect of arginine residues on
binding to CL is highly dependent on the positions that they
occupy in the sequence. The precise location of arginine
residues has been shown to be important in the binding of
both murine and human anti-dsDNA to DNA in numerous
studies [25,26,37]. Interestingly, Krishnan and colleagues
have demonstrated a strong correlation between specificity
for dsDNA and the relative position of arginine residues in
VH CDR3 [52,53]. They reported that the frequency of
arginine expression among murine anti-dsDNA antibodies
was highest at position 100, and they postulate that the
importance of this residue in binding to dsDNA lies in its
position at the centre of the VH CDR3 loop in the structure
of the antigen combining site [52]. Assuming that this loop
would be projected outward from the antigen combining
site, an arginine residue at position 100 would be located
at the apex of the VH CDR3 loop.
Conclusion
We have demonstrated the relative importance of certain
surface-exposed arginine residues at critical positions
within the light chain CDR1 and heavy chain CDR3 of dif-
ferent human monoclonal antibodies in conferring the abil-
ity to bind CL in a direct ELISA. It is now important to test
the effects of sequence changes involving these amino
acids on pathogenic functions of these aPL, by expressing
the altered antibodies in larger quantities from stably trans-
fected cells, and then testing them in bioassays.
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